NCT06952465Active, not recruiting
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
A Cohort Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis Using Administrative Health Claims Database
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 29 Apr 2025
- Start date
- 24 Jan 2025
- Primary completion date
- 30 Nov 2031
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT06952465
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 24 Jan 2025 to the primary completion date, 30 Nov 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with prescription in deucravacitinib or any biologics as comparator group prior to the index date.
- Participants with fewer than 12 months of available claim records prior to the index date.
- Specific for malignancy: Participants who had at least one disease code of malignancy prior to the index date
Other illness
- Specific for serious infection: Participants who had at least one disease code of hospitalized infection in the 60 days period before the index date.
Other
- Participants with no claims record within 1-year after the index date (no visit after the index date).
Who the study is looking for
- Participants with prescriptions in deucravacitinib or any biologics as comparator group during the indexing period.
- Participants with at least one confirmed diagnosis of disease code for psoriasis within 12 months prior to the index date.
- Aged 18 years or older at the index date
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Data Vision, Inc Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| - Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.